When does the new $675 price take effect?

January 1, 2027. Novo Nordisk announced the change on February 24, 2026.

Guide · Updated November 2026

Novo Nordisk’s 2027 Price Cut: Will Your Ozempic or Wegovy Bill Drop?

Novo Nordisk announced on February 24, 2026 that it's cutting the US list price of Wegovy, Ozempic, and Rybelsus to $675 a month, starting January 1, 2027. That's a real number, and it sounds like a straightforward win. It mostly isn't, at least not for you directly. List price and the price you pay at the counter are two different things, and Novo Nordisk said the change does not affect its direct-to-patient self-pay prices.

What Novo Nordisk announced

Per the company’s announcement, the new $675/month list price (wholesale acquisition cost) applies to Wegovy injection 2.4 mg and Wegovy tablets 25 mg, Ozempic injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus tablets 7 mg and 14 mg. The release says the decision applies to all doses of these medicines.

Novo Nordisk describes this as a cut of about 50% for Wegovy and about 35% for Ozempic. That lines up with the current list prices we track, about $1,349 a month for Wegovy and about $1,028 for Ozempic. The company says the change is aimed at people with high-deductible health plans or coinsurance benefit designs, whose costs are tied to list price.

One thing this announcement doesn’t touch: Mounjaro and Zepbound. Those are tirzepatide, made by Eli Lilly, a different company with a different drug. Nothing here changes their pricing.

Want the full current price breakdown?

Read the GLP-1 Cost Guide →

List price is not what you pay, and that’s the whole catch

List price, also called wholesale acquisition cost, is the sticker price a manufacturer sets before any negotiation happens. Almost nobody pays it. Insurers and the pharmacy benefit managers that negotiate on their behalf get rebates off that number, and the price a plan actually pays, the net price, is usually far lower. Patients with a flat copay (say, $25 or $50 for a covered prescription) pay that flat amount regardless of what the list price says.

So a list price cut by itself doesn’t guarantee your bill changes. The open question is whether Novo Nordisk’s rebates shrink to match the lower list price, in which case the net price insurers pay stays about the same and little changes for most patients, or whether the cut lowers what plans pay too. Novo Nordisk has not published its rebate terms.

Who’s most likely to see a real difference

Novo Nordisk’s own announcement points to two groups: people with high-deductible plans and people whose cost-sharing is calculated as a percentage of the drug’s price (coinsurance) rather than a flat dollar copay. If your plan has you paying, say, 20% of the list price instead of a flat fee, a lower list price directly lowers your share. A flat-copay patient won’t notice anything, because their copay isn’t tied to list price at all.

Not sure how your plan covers GLP-1s?

See the Insurance Coverage Guide →

Your cash price doesn’t move either

If you’re buying Ozempic, Wegovy, or Rybelsus without insurance, this announcement isn’t for you. Novo Nordisk stated that the list price change doesn’t affect its direct-to-patient self-pay prices, such as those sold through NovoCare Pharmacy. The release does not mention TrumpRx. As of Nov 4, 2026, the NovoCare Wegovy page lists the Wegovy pen at $349/month for the 1 mg, 1.7 mg, and 2.4 mg doses and $399/month for 7.2 mg, with new patients paying $199/month for their first two fills of 0.25 mg and 0.5 mg through December 31, 2026. It lists Wegovy pills at $149 to $299/month by dose. The page says pricing will be updated after December 31, 2026, so check it again before budgeting around any specific figure.

What to watch between now and January 2027

Nothing changes until the effective date, and even then, the change happens at the list-price level, not automatically at your pharmacy counter. A few things worth tracking as 2027 approaches:

Whether your specific plan passes the lower list price through to you. Ask your plan or PBM directly, since this isn’t something Novo Nordisk controls.
Whether rebates shrink to offset the cut. Reporting on this is early and based on analyst expectations, not confirmed PBM contracts, so treat any claim about net prices staying flat or dropping as a forecast, not a fact yet.
Whether your plan’s formulary tier changes. A lower list price can shift how a PBM tiers a drug, which affects your copay independent of the headline number.

Bottom Line

Novo Nordisk is cutting the list price of Wegovy, Ozempic, and Rybelsus to $675/month starting January 1, 2027, a roughly 50% cut for Wegovy and 35% for Ozempic. It doesn’t apply to Mounjaro or Zepbound, it doesn’t change cash self-pay prices, and for most patients with a flat copay it likely won’t change their bill at all. The patients most likely to feel it are the ones paying coinsurance tied to list price. If you want to know what you’ll pay, check your plan’s cost-sharing structure rather than assuming the new number applies to you.

FAQ

Does the $675 price apply to Zepbound or Mounjaro?

No. Those are tirzepatide, made by Eli Lilly. This price cut is specific to Novo Nordisk’s semaglutide products: Wegovy, Ozempic, and Rybelsus. Nothing in this announcement changes Lilly’s pricing.

Will my copay go down in 2027 because of this?

Probably not, unless your plan charges coinsurance (a percentage of the drug’s price) rather than a flat copay. Most patients with a flat copay pay the same amount regardless of list price, since their cost-sharing isn’t tied to that number.

Does this change the cash price for people without insurance?

No. Novo Nordisk said this list price change doesn’t affect its direct-to-patient self-pay prices, such as those through NovoCare. Its announcement does not mention TrumpRx.gov.

When does the new price take effect?

January 1, 2027. The announcement came on February 24, 2026, giving plans and PBMs roughly 10 months of lead time before the change takes effect.

Guides:

Compare: All Providers · All Guides

What we checked

This AI-assisted public-source desk check reviewed Novo Nordisk’s February 24, 2026 press release and the NovoCare Wegovy self-pay page on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.